Cystic fibrosis—cirrhosis, portal hypertension, and liver biopsy: Reply
Peter J. Lewindon, Grant A. Ramm – 31 January 2011
Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: An 11‐year single‐center experience
Hanaa Nafady‐Hego, Hamed Elgendy, Walid El Moghazy, Kazuhiko Fukuda, Shinji Uemoto – 31 January 2011 – Infection after pediatric living donor liver transplantation (LDLT) is a major cause of morbidity and mortality. Here, we sought to determine the incidence, timing, location, and risk factors for bacterial and fungal infections. We retrospectively investigated infection for 3 postoperative months in 345 consecutive pediatric patients (56.2% were females) who underwent primary LDLT at Kyoto University Hospital, Japan.
Portopulmonary hypertension as an indication for combined heart, lung, and liver or lung and liver transplantation: Literature review and case presentation
Nicole E. Scouras, Takashi Matsusaki, Charles D. Boucek, Cynthia Wells, Erik A. Cooper, Raymond M. Planinsic, Erin A. Sullivan, Christian A. Bermudez, Yoshiya Toyoda, Tetsuro Sakai – 28 January 2011 – End‐stage liver disease with severe portopulmonary hypertension (PPHTN), which is refractory to vasodilator therapies, is a contraindication for isolated liver transplantation (LT) because of the high mortality rate.
Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein
See Ching Chan, Chung Mau Lo, Kelvin K.C. Ng, Irene O.L. Ng, Boon Hun Yong, Sheung Tat Fan – 28 January 2011 – The middle hepatic vein may be included in right liver living donor liver transplantation (LDLT) to optimize hepatic venous outflow. We studied the graft's ability to relieve portal hypertension and accommodate portal hyperperfusion with portal manometry and ultrasonic flowmetry. Surgical outcomes with respect to portal hemodynamometry were also investigated.
Health care reform: How personalized medicine could help bundling of care for liver diseases
Lopa Mishra – 27 January 2011
Ribavirin enhances interferon‐stimulated gene transcription by activation of the interferon‐stimulated response element
Qiuwei Pan, Hugo W. Tilanus, Harry L.A. Janssen, Luc J. W. van der Laan – 27 January 2011
Of mice and men: The nonrandom genomic instability in hepatocarcinogenesis
Diego F. Calvisi – 27 January 2011
A woman with improving cholestasis but hepatitis aggravating
Hao‐Chun Yu, Yung‐Hsiang Hsu, Chi‐Tan Hu – 27 January 2011
Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma
Seung‐Oe Lim, Young Min Park, Hyeon Seop Kim, Xiaoyuan Quan, Jeong Eun Yoo, Young Nyun Park, Gi Hong Choi, Guhung Jung – 27 January 2011 – The tumor suppressor p53 is a key prognostic factor in hepatocellular carcinoma (HCC), yet only 35% of grade III tumors exhibit mutation of p53. Several other pathways have been implicated in HCC and, among these, the role of the Notch1/Snail pathway remains unclear. Therefore, we investigated the expression of p53, Notch1, and Snail proteins in HCC with regard to both clinical grade and p53 mutational status.
Fibrinogen‐γ proteolysis and solubility dynamics during apoptotic mouse liver injury: Heparin prevents and treats liver damage
Sujith V. W. Weerasinghe, David S. Moons, Peter J. Altshuler, Yatrik M. Shah, M. Bishr Omary – 27 January 2011 – Fas ligand (FasL)‐mediated hepatocyte apoptosis occurs in the context of acute liver injury that can be accompanied by intravascular coagulation (IC). We tested the hypothesis that analysis of selected protein fractions from livers undergoing apoptosis will shed light on mechanisms that are involved in liver injury that might be amenable to intervention.